News

Apply Now for the Shauna M. Sorrells Program

In 2020, G2G Consulting launched the Shauna M. Sorrells Program to provide a $10,000 grant to a nonprofit that dedicates meaningful services and programs to women and children, especially women of color.

Award winners have provided programming in breast cancer screening services, maternal health, housing, STEM education programs, adult literacy, domestic violence shelter, and career advancement services.

⮕ How it Works:

Grants are for small nonprofits providing services to women and children and communities of color. All applicants must be a nonprofit with an annual budget of $3 million or less. Preference is granted to organizations serving women and children, especially people of color. If you have been awarded grants twice before, you are not eligible for funding. Once three finalists are selected, the voting begins to select the Grand Prize Winner.

Applications are open October 1 – 27.

 

Apply Now

Recent News

10/01/2025

Apply Now for the Shauna M. Sorrells Program

In 2020, G2G Consulting launched the Shauna M. Sorrells Program to provide a $10,000 grant to a nonprofit that dedicates meaningful services and programs to women and children, especially women of color. Award winners have provided programming in breast cancer screening services, maternal health, housing, STEM education programs, adult literacy, domestic violence shelter, and career

10/01/2025

Apply now for the ATCC Innovation Challenge

ATCC is excited to launch their 2025 Innovation Challenge, inviting researchers to explore bold, creative applications of their ThawReady™ Assay Ready Cells, an innovative line of products  designed to accelerate cell-based assays and eliminate the need for lengthy cell expansion and banking prior to starting bioassays, saving valuable time and money. Running through November 30,

09/29/2025

Serpin Pharma and Dogwood Therapeutics Partner to Advance SP16 for Cancer-Related Pain

Serpin Pharma has entered a strategic partnership with Dogwood Therapeutics to develop and commercialize SP16, a first-in-class LRP1 agonist targeting chemotherapy-induced peripheral neuropathy (CIPN). SP16 IV, the intravenous formulation, has shown dual anti-inflammatory and neural repair effects in preclinical studies and will enter a Phase 1b trial in early 2026, fully funded by the National